Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02202135|
Recruitment Status : Terminated (Overall study status is changed to "Terminated" due to low enrollment)
First Posted : July 28, 2014
Results First Posted : March 31, 2016
Last Update Posted : September 6, 2017
Information provided by (Responsible Party):
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment|
Complicated Skin and Soft Tissue Infection
Drug: Ceftaroline fosamil
|Recruitment Details||Overall, 4 patients were enrolled from 2 centres in 1 regions in this study. The first patient was enrolled on 15 September 2014 and the last patient last visit was on 02 January 2015.|
|Arm/Group Description||Ceftaroline fosamil 600 mg 120 min|
|Period Title: Overall Study|
Early termination leading to small number of subjects analyzed.